Biomarkers in synucleinopathies

Abstract

Clinicians need reliable diagnostic and prognostic biomarkers for synucleinopathies including Parkinson's disease. The diagnosis of Parkinson's disease mostly depends on clinical findings, and recent research identified that the potential diagnostic and prognostic value of CSF and blood biomarkers closely reflecting the pathophysiology of Parkinson's disease, such as α–synuclein. And recent research developed the detection methods based on amplification of synuclein seeds (e.g. RT–QuIC or PMCA). So we introduced that αSyn seeding activity may serve as a novel biomarker for antemortem diagnoses of PD and other synucleinopathies.